Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.

Gerich JE, Bastien A.

Expert Rev Clin Pharmacol. 2011 Nov;4(6):669-83. doi: 10.1586/ecp.11.54. Review.

PMID:
22111852
2.

Dapagliflozin: an emerging treatment option in type 2 diabetes.

Kipnes M.

Expert Opin Investig Drugs. 2009 Mar;18(3):327-34. doi: 10.1517/13543780902766794 . Review.

PMID:
19243283
3.

Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.

Jabbour SA, Whaley JM, Tirmenstein M, Poucher SM, Reilly TP, Boulton DW, Saye J, List JF, Parikh S.

Postgrad Med. 2012 Jul;124(4):62-73. doi: 10.3810/pgm.2012.07.2569. Review.

PMID:
22913895
4.

[Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].

Albarrán OG, Ampudia-Blasco FJ.

Med Clin (Barc). 2013 Sep;141 Suppl 2:36-43. doi: 10.1016/S0025-7753(13)70062-9. Review. Spanish.

PMID:
24444523
6.

[Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].

Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S.

Dtsch Med Wochenschr. 2013 Apr;138 Suppl 1:S16-26. doi: 10.1055/s-0032-1305277. Epub 2013 Mar 25. German.

PMID:
23529567
7.

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.

Kaku K, Inoue S, Matsuoka O, Kiyosue A, Azuma H, Hayashi N, Tokudome T, Langkilde AM, Parikh S.

Diabetes Obes Metab. 2013 May;15(5):432-40. doi: 10.1111/dom.12047. Epub 2013 Jan 25.

PMID:
23194084
8.

Dapagliflozin for the treatment of type 2 diabetes.

Brooks AM, Thacker SM.

Ann Pharmacother. 2009 Jul;43(7):1286-93. doi: 10.1345/aph.1M212. Epub 2009 Jul 7. Review.

PMID:
19584379
9.

Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.

Shah NK, Deeb WE, Choksi R, Epstein BJ.

Pharmacotherapy. 2012 Jan;32(1):80-94. doi: 10.1002/PHAR.1010. Review.

PMID:
22392830
10.

Dapagliflozin for the treatment of type 2 diabetes.

Anderson SL, Marrs JC.

Ann Pharmacother. 2012 Apr;46(4):590-8. doi: 10.1345/aph.1Q538. Epub 2012 Mar 20. Review.

PMID:
22433611
11.

Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.

Vivian EM.

Am J Health Syst Pharm. 2015 Mar 1;72(5):361-72. doi: 10.2146/ajhp140168. Review.

PMID:
25694411
12.

Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.

Kaku K, Kiyosue A, Inoue S, Ueda N, Tokudome T, Yang J, Langkilde AM.

Diabetes Obes Metab. 2014 Nov;16(11):1102-10. doi: 10.1111/dom.12325. Epub 2014 Jul 8.

PMID:
24909293
13.

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.

Neumiller JJ, White JR Jr, Campbell RK.

Drugs. 2010 Mar 5;70(4):377-85. doi: 10.2165/11318680-000000000-00000. Review.

PMID:
20205482
14.

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.

Kasichayanula S, Liu X, Pe Benito M, Yao M, Pfister M, LaCreta FP, Humphreys WG, Boulton DW.

Br J Clin Pharmacol. 2013 Sep;76(3):432-44. doi: 10.1111/bcp.12056.

15.

Dapagliflozin: a review on efficacy, clinical effectiveness and safety.

Paisley AN, Yadav R, Younis N, Rao-Balakrishna P, Soran H.

Expert Opin Investig Drugs. 2013 Jan;22(1):131-40. doi: 10.1517/13543784.2013.740009. Epub 2012 Nov 6. Review. Erratum in: Expert Opin Investig Drugs. 2013 Jul;22(7):939. Paisley, Angela J [corrected to Paisley, Angela N].

PMID:
23127205
16.

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW.

Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. Review.

PMID:
24105299
17.

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight.

Zhang L, Feng Y, List J, Kasichayanula S, Pfister M.

Diabetes Obes Metab. 2010 Jun;12(6):510-6. doi: 10.1111/j.1463-1326.2010.01216.x.

PMID:
20518806
18.

Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.

Davidson JA, Kuritzky L.

Postgrad Med. 2014 Oct;126(6):33-48. doi: 10.3810/pgm.2014.10.2819. Review.

PMID:
25414933
19.

Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.

Raskin P.

Diabetes Metab Res Rev. 2013 Jul;29(5):347-56. doi: 10.1002/dmrr.2403. Review.

PMID:
23463735
20.

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.

Kasichayanula S, Chang M, Hasegawa M, Liu X, Yamahira N, LaCreta FP, Imai Y, Boulton DW.

Diabetes Obes Metab. 2011 Apr;13(4):357-65. doi: 10.1111/j.1463-1326.2011.01359.x.

PMID:
21226818

Supplemental Content

Support Center